文献速递肝胆胰外科围术期管理与 ERAS

代谢综合征肝细胞癌微创与开腹肝切除对比研究

Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome.
PubMed 文献 · Ann Surg · 2023-03-30

这项多中心研究纳入996例代谢综合征合并肝细胞癌患者,采用倾向评分加权比较微创与开腹肝切除。微创组大并发症、肝衰竭、胆漏和腹水发生率更低,住院时间更短,总生存和无病生存无显著差异。

要点

  • 微创肝切除组大并发症发生率显著低于开腹组(9.3% vs 15.3%,P=0.015)。
  • 微创组术后肝衰竭(0.6% vs 4.3%)、胆漏(2.2% vs 6.4%)和腹水发生率更低。
  • 两组总生存和无病生存无显著差异,微创组住院时间更短。

核心结论

  • 代谢综合征合并肝细胞癌患者行微创肝切除的围术期和肿瘤学结局与开腹肝切除相当。
  • 微创肝切除可减少大并发症、术后肝衰竭、腹水和胆漏,并缩短住院时间。
  • 在条件允许时,微创肝切除应作为代谢综合征患者的优先选择。

研究设计与样本

  • 多中心研究,共涉及24家机构。
  • 共纳入996例患者,开腹肝切除580例,微创肝切除416例。
  • 采用倾向评分计算和逆概率加权进行组间比较。

主要发现

  • 加权后两组基线匹配良好,失血量相似(开腹组275.9±3.1 vs 微创组226±4.0,P=0.146)。
  • 90天并发症发生率(38.9% vs 31.9%,P=0.08)和死亡率(2.4% vs 2.2%,P=0.84)无显著差异。
  • 微创组大并发症(9.3% vs 15.3%,P=0.015)、术后肝衰竭(0.6% vs 4.3%,P=0.008)、胆漏(2.2% vs 6.4%,P=0.003)发生率显著更低。
  • 微创组术后第1天腹水发生率(2.7% vs 8.1%,P=0.002)和第3天腹水发生率(3.1% vs 11.4%,P<0.001)显著更低。
  • 微创组住院时间显著更短(5.8±1.9 vs 7.5±1.7,P<0.001),总生存和无病生存无显著差异。

临床怎么用

  • 对于代谢综合征合并肝细胞癌且适合手术的患者,可优先考虑微创肝切除。
  • 微创肝切除有助于降低术后肝衰竭、胆漏和腹水等严重并发症风险。
  • 微创肝切除可缩短住院时间,且不牺牲肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare minimally invasive (MILR) and open liver resections (OLRs) for hepatocellular carcinoma (HCC) in patients with metabolic syndrome (MS). BACKGROUND: Liver resections for HCC on MS are associated with high perioperative morbidity and mortality. No data on the minimally invasive approach in this setting exist. MATERIAL AND METHODS: A multicenter study involving 24 institutions was conducted. Propensity scores were calculated, and inverse probability weighting was used to weight comparisons. Short-term and long-term outcomes were investigated. RESULTS: A total of 996 patients were included: 580 in OLR and 416 in MILR. After weighing, groups were well matched. Blood loss was similar between groups (OLR 275.9±3.1 vs MILR 226±4.0, P =0.146). There were no significant differences in 90-day morbidity (38.9% vs 31.9% OLRs and MILRs, P =0.08) and mortality (2.4% vs 2.2% OLRs and MILRs, P =0.84). MILRs were associated with lower rates of major complications (9.3% vs 15.3%, P =0.015), posthepatectomy liver failure (0.6% vs 4.3%, P =0.008), and bile leaks (2.2% vs 6.4%, P =0.003); ascites was significantly lower at postoperative day 1 (2.7% vs 8.1%, P =0.002) and day 3 (3.1% vs 11.4%, P <0.001); hospital stay was significantly shorter (5.8±1.9 vs 7.5±1.7, P <0.001). There was no significant difference in overall survival and disease-free survival. CONCLUSIONS: MILR for HCC on MS is associated with equivalent perioperative and oncological outcomes to OLRs. Fewer major complications, posthepatectomy liver failures, ascites, and bile leaks can be obtained, with a shorter hospital stay. The combination of lower short-term severe morbidity and equivalent oncologic outcomes favor MILR for MS when feasible.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Berardi G, Ivanics T, Sapisochin G, et al. Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome. Ann Surg. 2023. PMID: 36994755. doi:10.1097/SLA.0000000000005861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。